Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Change in Receivables (2020 - 2023)

Pliant Therapeutics (PLRX) has disclosed Change in Receivables for 4 consecutive years, with -$1.6 million as the latest value for Q3 2023.

  • On a quarterly basis, Change in Receivables rose 54.95% to -$1.6 million in Q3 2023 year-over-year; TTM through Jun 2024 was -$1.6 million, a 53.65% increase, with the full-year FY2023 number at -$2.0 million, down 13120.0% from a year prior.
  • Change in Receivables was -$1.6 million for Q3 2023 at Pliant Therapeutics, up from -$1.7 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $24.7 million in Q1 2020 to a low of -$28.2 million in Q2 2020.
  • A 4-year average of -$470133.3 and a median of -$220000.0 in 2021 define the central range for Change in Receivables.
  • Biggest YoY gain for Change in Receivables was 1187.21% in 2022; the steepest drop was 1494.09% in 2022.
  • Pliant Therapeutics' Change in Receivables stood at $2.1 million in 2020, then crashed by 81.94% to $388000.0 in 2021, then increased by 29.12% to $501000.0 in 2022, then tumbled by 415.37% to -$1.6 million in 2023.
  • Per Business Quant, the three most recent readings for PLRX's Change in Receivables are -$1.6 million (Q3 2023), -$1.7 million (Q2 2023), and $1.3 million (Q1 2023).